Three Former WHO Officials Say Tobacco Harm Reduction Could Accelerate the End of Smoking
A new debate around global tobacco control is gaining attention after three former senior officials from the World Health Organization publicly argued that tobacco harm reduction — including the use of e-cigarettes and nicotine pouches — deserves a far bigger role in global public health policy.
In a recent commentary published in the journal Nature Health, former WHO leaders Robert Beaglehole, Ruth Bonita, and Tikki Pang stated that the world could potentially reduce global smoking prevalence below 5% by 2040 if regulators adopted a more pragmatic approach toward safer nicotine alternatives.
The article, titled “Smoke-Free Nicotine Products Can Accelerate the End of Smoking,” argues that current tobacco control policies have overlooked one of the original pillars of the WHO Framework Convention on Tobacco Control (FCTC): harm reduction.
According to the authors, the FCTC has helped reduce smoking rates over the past two decades, but progress is slowing in many countries. Smoking still causes more than 7 million deaths globally every year, and traditional anti-smoking strategies alone may no longer be enough to drive smoking rates dramatically lower.
“The Problem Is Smoke, Not Nicotine”
One of the central arguments made by the former WHO officials is that many public health organizations increasingly treat nicotine itself as the primary enemy, despite decades of scientific evidence suggesting otherwise.
Robert Beaglehole, former Director of WHO’s Department of Chronic Disease and Health Promotion, said that conflating nicotine use with smoking-related disease has created unnecessary resistance toward reduced-risk products such as e-cigarettes, heated tobacco products, and nicotine pouches.
The article emphasizes a distinction frequently raised in harm reduction research:
Nicotine is addictive, but it is not the main cause of smoking-related cancers or cardiovascular disease.
The overwhelming harm from cigarettes comes from combustion and toxic smoke inhalation.
Non-combustible nicotine products may significantly reduce exposure to harmful chemicals for adult smokers who completely switch away from cigarettes.
Several international health agencies and scientific reviews were referenced in support of this position.
The UK’s National Health Service has repeatedly stated that switching completely from smoking to vaping can substantially reduce exposure to toxins linked to lung disease, heart disease, and stroke.
Meanwhile, reviews from the National Academies of Sciences, Engineering, and Medicine have concluded that e-cigarettes are likely far less harmful than combustible cigarettes.
Biomarker studies cited by harm reduction advocates also suggest that smokers who fully transition to vaping can reduce exposure to tobacco-specific carcinogens such as NNAL and NNN by more than 90%, with some measurements approaching levels found in non-smokers.
Countries Embracing Harm Reduction Are Seeing Faster Declines
The former WHO officials also pointed to several countries where smoking rates have fallen rapidly after reduced-risk nicotine products became widely available.
Sweden
Sweden is often highlighted as the world’s leading example of tobacco harm reduction. Through widespread use of snus and other smoke-free nicotine products, the country has reduced smoking prevalence to below 5%, effectively reaching “smoke-free” status under many public health definitions.
United Kingdom
The UK has taken one of the most supportive regulatory approaches toward vaping among major Western countries.
Public health agencies and stop-smoking services openly recommend vaping as a smoking cessation tool, and vaping has become one of the most commonly used methods for quitting smoking in Britain.
Recent UK statistics reportedly showed adult vaping prevalence surpassing traditional smoking rates for the first time, while national smoking rates continued a long-term decline from over 20% in 2011 to near 10% in recent years.
Some regional NHS stop-smoking programs already provide vaping products to adult smokers, and the UK is also exploring prescription-based vaping pathways for smoking cessation.
New Zealand
New Zealand’s experience was also cited as a major policy turning point.
According to the article, smoking rates declined relatively slowly under conventional tobacco control measures alone. However, after the country relaxed restrictions on vaping products in 2018, smoking prevalence reportedly fell much faster, eventually reaching around 6.8%.
Criticism of WHO’s Current Direction
The article also criticized what the authors describe as an increasingly rigid anti-nicotine approach within parts of the global tobacco control movement.
At the 11th Conference of the Parties (COP11) to the FCTC in late 2025, New Zealand reportedly received the controversial “Dirty Ashtray Award” from anti-tobacco advocacy groups aligned with WHO positions, largely due to its support for tobacco harm reduction policies.
Critics argue that this reflects a growing divide within public health circles:
Some experts prioritize total nicotine elimination.
Others believe reducing smoking-related disease should remain the primary objective, even if nicotine use continues through lower-risk alternatives.
The three former WHO officials argue that countries successfully lowering smoking rates through harm reduction strategies should be studied rather than dismissed.
What the Former WHO Officials Want to Change
The authors are not calling for deregulation. Instead, they propose a dual-track strategy:
Stronger restrictions and taxation on combustible cigarettes.
Clear regulatory frameworks for vaping products and nicotine pouches.
Product safety standards.
Strict youth access prevention measures.
Easier access to lower-risk alternatives for adult smokers.
In interviews following publication of the article, Robert Beaglehole said he remains optimistic that scientific evidence will eventually shift global policy discussions.
He suggested future WHO leadership may become more open to tobacco harm reduction as additional long-term evidence continues to emerge.
The Bigger Global Debate
The discussion around vaping and harm reduction remains one of the most divisive issues in modern public health.
Critics of vaping continue to raise concerns about youth uptake, nicotine addiction, product marketing, and long-term health uncertainty.
Supporters counter that refusing to differentiate between combustible cigarettes and lower-risk alternatives could slow progress in reducing smoking-related disease among adults who are unable or unwilling to quit nicotine entirely.
What is becoming increasingly clear is that the global conversation is shifting. With former WHO leaders now openly challenging existing orthodoxy, tobacco harm reduction is likely to remain at the center of international nicotine policy debates for years to come.
Vape Daily Brief — Stay Updated 24/7